Key takeaways

• Zonulin is a signalling protein that reversibly loosens the tight junctions between intestinal epithelial cells, raising paracellular permeability.
• It was identified as pre-haptoglobin-2, the uncleaved precursor of haptoglobin-2, so it is a human protein — not a dietary component.
• Gluten and bacterial exposure are the two best-established triggers of zonulin release.
• Raised zonulin has been reported in coeliac disease, type 1 diabetes and inflammatory bowel disease, with weaker and more preliminary associations elsewhere.
• Zonulin is a research biomarker rather than a diagnostic test; coeliac disease is diagnosed by serology and biopsy, not by zonulin.
• Because no single marker captures barrier function, zonulin is usually measured alongside tight junction proteins and markers of epithelial damage or endotoxin exposure.
• Larazotide acetate is the most advanced zonulin-directed candidate, but its phase 3 trial in coeliac disease was stopped early for futility in 2022.

Contents

• What zonulin is and where it comes from
• Tight junctions and the intestinal barrier
• What “leaky gut” means
• How zonulin works
• The structure and identity of zonulin
• Zonulin in disease
• Zonulin and bacterial adhesion
• How zonulin is measured
• Managing zonulin-related disorders
• Zonulin inhibitors
• Choosing a barrier assay
• Frequently asked questions

Intestinal barrier assay kits

Barrier integrity is a composite readout, so zonulin is rarely measured alone. The panel below pairs zonulin with the structural tight junction proteins and the two most widely used markers of epithelial damage and endotoxin translocation.

Zonulin

Human Zonulin ELISA Kit

Sandwich ELISAHuman

Quantifies zonulin in serum, plasma and stool for studies of intestinal permeability.

View kit →

ZO-1

Human TJP1 / ZO-1 ELISA Kit

Sandwich ELISAHuman

Measures the scaffolding protein that anchors tight junction strands to the cytoskeleton.

View kit →

OCLN

Human Occludin ELISA Kit

Sandwich ELISAHuman

Quantifies occludin, an integral tight junction protein central to barrier regulation.

View kit →

CLDN1

Human Claudin-1 ELISA Kit

Sandwich ELISAHuman

Claudins determine the selectivity of the paracellular pore; claudin-1 is a sealing member.

View kit →

I-FABP

Human I-FABP / FABP2 ELISA Kit

Sandwich ELISAHuman

Released on enterocyte damage — a direct marker of intestinal epithelial injury.

View kit →

LBP

Human LBP ELISA Kit

Sandwich ELISAHuman

Lipopolysaccharide-binding protein, used as an indirect index of bacterial endotoxin translocation.

View kit →

What zonulin is and where it comes from

Zonulin is an endogenous signalling protein that regulates the permeability of the intestinal barrier. It acts on the tight junctions between the epithelial cells lining the gut, loosening them so that molecules can pass between cells rather than through them. Under normal conditions this is a controlled, reversible process — the barrier is meant to open and close, not to stay shut. When zonulin release becomes excessive or persistent, permeability rises beyond what the barrier can tolerate, and material that should have stayed in the lumen reaches the underlying tissue and circulation.

It is produced chiefly by intestinal epithelial cells, and expression has also been reported in the liver, kidney, heart, brain and immune cells. One point deserves emphasis because it is widely misstated: zonulin is a human protein, and foods do not contain it. Gluten-containing grains are frequently described as being “high in zonulin”, which is not correct. What gluten does — specifically the gliadin fraction — is trigger the release of zonulin from the intestinal epithelium. The distinction matters: the protein in question is yours, and diet modulates its secretion rather than supplying it.

Tight junctions and the intestinal barrier

Tight junctions are specialised protein complexes that seal the space between adjacent epithelial and endothelial cells. They do not simply glue cells together; they form a selective, regulated gate that determines which ions and small molecules may pass through the paracellular route. The same machinery operates in the intestinal lining, the blood-brain barrier and the kidney tubule, which is why barrier biology recurs across otherwise unrelated fields.

Four families of protein do most of the work. Claudins are the transmembrane proteins that form the paracellular pore and set its charge selectivity, with some members sealing the barrier and others forming channels. Occludin is a second integral membrane protein involved in regulating and maintaining the junction. Junctional adhesion molecules contribute to adhesion and to leukocyte trafficking across the epithelium. And the zonula occludens proteins, ZO-1, ZO-2 and ZO-3, sit on the cytoplasmic face as scaffolds, linking the transmembrane components to the actin cytoskeleton — which is how a junction can be actively pulled open rather than merely leaking.

What “leaky gut” means

Increased intestinal permeability — popularly “leaky gut” — describes a state in which the epithelial barrier admits more material than it should, allowing bacterial products, antigens and incompletely digested food constituents to reach the lamina propria and the portal circulation. The immune consequence is chronic low-grade activation, and increased permeability is a well-documented feature of coeliac disease, Crohn’s disease and ulcerative colitis.

It is worth being precise about the causal claim, because this is where the popular and scientific literatures diverge. Increased permeability is firmly established as a measurable phenomenon and as a feature of several diseases. Whether it is a cause of those diseases, a consequence of the inflammation they produce, or both, is far less settled, and “leaky gut syndrome” as a standalone diagnosis explaining diffuse symptoms is not a recognised clinical entity. Documented contributors to raised permeability include chronic inflammatory states, enteric infection, chemotherapy and radiotherapy, prolonged NSAID use, and heavy alcohol intake.

How zonulin works

Zonulin’s function is to make the tight junction adjustable. Released into the lumen and acting on the apical surface of the epithelium, it initiates a signalling cascade that leads to reorganisation of the junctional complex and the cytoskeleton beneath it, so the paracellular space opens. The accepted model involves engagement of protease-activated receptor 2 and transactivation of the epidermal growth factor receptor, followed by protein kinase C-dependent rearrangement of ZO-1 and occludin away from the junction and contraction of the actin cytoskeleton. The effect is transient: withdraw the stimulus and the junction reassembles.

Physiologically this is useful. Regulated opening permits sampling of luminal antigen by the mucosal immune system, contributes to fluid and solute movement, and participates in epithelial repair. The problem is not zonulin itself but the loss of proportion — sustained release keeps junctions open when they should be closed.

Two triggers are well established. Gliadin, the alcohol-soluble fraction of gluten, induces zonulin release from intestinal epithelium, and does so more markedly in tissue from people with coeliac disease. Bacterial exposure is the other: enteric colonisation, particularly by organisms reaching the small intestine, provokes zonulin secretion, which is consistent with the protein having evolved as part of an innate response that flushes the lumen by opening the barrier.

The structure and identity of zonulin

Zonulin was originally defined by its activity rather than its sequence, and was later identified as pre-haptoglobin-2, the uncleaved precursor of haptoglobin-2. This resolved a long-standing puzzle and it corrects a claim that circulates widely: there is no gene called ZONULIN, and no subunits named ZON1 and ZON2. Zonulin is encoded by the haptoglobin gene, HP, on chromosome 16.

Haptoglobin normally circulates as a mature two-chain protein, an alpha chain and a beta chain, generated by proteolytic cleavage of a single-chain precursor. It is the uncleaved precursor of the haptoglobin-2 allelic variant that carries zonulin activity, with the beta-chain portion mediating receptor engagement and the signalling that opens the junction. Because the relevant activity belongs to the precursor rather than the mature protein, and because only the HP2 allele yields it, an individual’s haptoglobin genotype influences their capacity to produce zonulin at all — a genuinely interesting link between a common polymorphism and barrier physiology.

Zonulin in disease

Raised zonulin has been reported across a wide range of conditions, but the associations differ enormously in how well established they are, and lumping them together overstates the weaker ones. The table below separates them.

Coeliac disease is the clearest case, because there the mechanism and the association point the same way: gluten ingestion triggers zonulin release, permeability rises, and gluten peptides reach the immune system to drive the autoimmune response against the small intestinal mucosa. For most of the other entries the honest summary is that permeability and zonulin are altered, and that whether this contributes to the disease or reflects it remains an open question. The neurological and oncological associations in particular rest on small studies and should be read as hypotheses rather than findings.

Zonulin and bacterial adhesion

The relationship between zonulin and bacteria runs in both directions. Bacterial exposure in the small intestine induces zonulin secretion, and the resulting increase in permeability appears to be part of an innate defensive response — opening the barrier draws fluid into the lumen and helps flush colonising organisms out. Read this way, zonulin is not a defect but a mechanism whose chronic activation becomes harmful.

The reverse effect has also been described: higher zonulin and a looser barrier are associated with increased bacterial adhesion to the epithelium, which sustains local inflammation and further permeability. In coeliac disease, where zonulin release is exaggerated, both raised zonulin and altered bacterial adherence have been reported together, suggesting a self-reinforcing loop rather than a simple one-way relationship.

How zonulin is measured

Zonulin is most commonly quantified by sandwich ELISA in serum or plasma, and in stool where an index of local intestinal release is wanted. To be clear about what the assay does, since this is often garbled: the ELISA uses antibodies as capture and detection reagents to measure the zonulin protein. It does not measure antibodies against zonulin, and there is no such thing as a zonulin antibody test in this context.

Zonulin is a research biomarker, not a diagnostic test

This point matters clinically. Zonulin is used in research to compare groups and track change over time; it is not a validated diagnostic test for coeliac disease, type 1 diabetes or inflammatory bowel disease, and it should not be presented as one. Coeliac disease is diagnosed by serology — tissue transglutaminase IgA in the first instance — followed by duodenal biopsy while the patient is still consuming gluten. Inflammatory bowel disease is diagnosed by endoscopy, histology and imaging, with faecal calprotectin used to distinguish inflammatory from functional bowel disease. Type 1 diabetes is diagnosed on glycaemia with islet autoantibodies for confirmation. Zonulin adds mechanistic information alongside these; it does not substitute for any of them.

Managing zonulin-related disorders

There is no treatment aimed at zonulin in clinical use. Management addresses the underlying condition, and where that condition is driven by a zonulin trigger, removing the trigger is the effective intervention.

For coeliac disease that means a strict lifelong gluten-free diet, which removes the stimulus for zonulin release, allows the mucosa to heal and normalises permeability over time. Type 1 diabetes requires insulin replacement. Inflammatory bowel disease is managed with anti-inflammatory agents, immunomodulators, biologics targeting cytokines or integrins, and surgery where medical therapy fails. For the conditions with only preliminary zonulin associations, there is no basis for treatment directed at permeability at all. Anyone with symptoms suggesting one of these diagnoses needs proper assessment rather than self-directed intervention, and this article is not clinical advice.

Zonulin inhibitors

Blocking zonulin signalling to hold tight junctions closed is an attractive idea, and it has been pursued furthest in coeliac disease. Progress has been more difficult than early results suggested.

Larazotide acetate

Larazotide acetate, also known as AT-1001, is a synthetic octapeptide that acts locally in the gut lumen to antagonise zonulin-mediated tight junction opening, promoting reassembly of the junction rather than being absorbed systemically. It performed encouragingly in phase 2 as an adjunct to a gluten-free diet, and in 2020 became the first coeliac disease drug to reach phase 3. That trial, CedLara, was discontinued in June 2022: a pre-specified interim analysis conducted at roughly half of target enrolment concluded that the number of additional patients required to demonstrate a statistically significant effect was too large to justify continuing. Strictly, then, it was halted for futility rather than having formally missed its endpoint — but either way no zonulin-directed therapy is approved, and a good deal of secondary writing still describes larazotide as though approval were imminent.

Polyphenols

Resveratrol, curcumin and quercetin have been reported to support tight junction integrity and reduce permeability in cell and animal models, with effects attributed variously to antioxidant activity, inhibition of inflammatory signalling and direct effects on junctional proteins. The evidence is preclinical; describing them as zonulin inhibitors in humans overstates what has been shown.

Probiotics and the microbiota

Particular Lactobacillus and Bifidobacterium strains improve barrier function in experimental models and, in some trials, lower circulating zonulin. The mechanism is indirect — competition with adherent organisms, short-chain fatty acid production, dampened mucosal inflammation — rather than zonulin antagonism, and effects are strain-specific, so results with one product do not generalise.

Removing the trigger

The most reliable way to reduce zonulin-driven permeability remains eliminating what provokes it. In coeliac disease that is gluten, and strict avoidance is both the established treatment for the disease and the most effective available means of normalising zonulin.

Frequently asked questions